Malignant Solid Tumors Clinical Trial
Official title:
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized [1-13C] pyruvate (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced. The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05539677 -
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
|
||
| Completed |
NCT05594147 -
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
|
||
| Not yet recruiting |
NCT06082557 -
A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05508620 -
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02902237 -
tTF-NGR Phase I Study
|
Phase 1 | |
| Recruiting |
NCT05441046 -
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT03205176 -
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
|
Phase 1 | |
| Completed |
NCT01765790 -
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
|
Phase 1 | |
| Completed |
NCT05930457 -
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01694472 -
Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors
|
Phase 1 | |
| Completed |
NCT01391533 -
Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT00516438 -
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
|
Phase 1 | |
| Completed |
NCT01519817 -
Cancer Vaccine Targeting Brachyury Protein in Tumors
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
| Recruiting |
NCT05579275 -
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT05814835 -
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT02805166 -
PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy
|
Phase 4 |